These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 24061864

  • 21. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
    van den Bongard HJ, Mathôt RA, van Tellingen O, Schellens JH, Beijnen JH.
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):16-24. PubMed ID: 12111107
    [Abstract] [Full Text] [Related]

  • 22. Population pharmacokinetics of PM00104 (Zalypsis(®)) in cancer patients.
    Pérez-Ruixo C, Valenzuela B, Fernández Teruel C, González-Sales M, Miguel-Lillo B, Soto-Matos A, Pérez-Ruixo JJ.
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):15-24. PubMed ID: 21590449
    [Abstract] [Full Text] [Related]

  • 23. Population pharmacokinetics and renal toxicity of cisplatin in cancer patients with renal dysfunction.
    Morita-Ogawa T, Sugita H, Minami H, Yamaguchi T, Hanada K.
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):559-566. PubMed ID: 32949266
    [Abstract] [Full Text] [Related]

  • 24. Lack of effect of smoking status on axitinib pharmacokinetics in patients with non-small-cell lung cancer.
    Garrett M, Taylor T, Mould DR, Amantea MA, Chen Y, Ingrosso A, Pithavala YK.
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1131-1141. PubMed ID: 27783139
    [Abstract] [Full Text] [Related]

  • 25. Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients.
    Evelina Cardoso, Guidi M, Khoudour N, Pascaline Boudou-Rouquette, Fabre E, Tlemsani C, Arrondeau J, François Goldwasser, Vidal M, Schneider MP, Wagner AD, Widmer N, Blanchet B, Csajka C.
    Clin Ther; 2020 Jul; 42(7):1302-1316. PubMed ID: 32631634
    [Abstract] [Full Text] [Related]

  • 26. Effect of age on systemic exposure and haematological toxicity of carboplatin in advanced non-small cell lung cancer patients.
    Merino-Sanjuán M, Monteiro JF, Porta-Oltra B, Maestu I, Almenar D, Jiménez-Torres NV.
    Basic Clin Pharmacol Toxicol; 2011 Dec; 109(6):457-64. PubMed ID: 21726412
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Pharmacokinetics of an etoposide infused over three days: concomitant infusion with cisplatin.
    Minami H, Horio Y, Sakai S, Saka H, Shimokata K.
    Jpn J Clin Oncol; 1991 Dec; 21(6):400-5. PubMed ID: 1666659
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
    Belli L, LeChevalier T, Gottfried M, Adams D, Ruffie P, LeCesne A, Tete L, Pellae-Cosset B.
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Population pharmacokinetics of hyperthermic intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis after cytoreductive surgery.
    Pérez-Ruixo C, Valenzuela B, Peris JE, Bretcha-Boix P, Escudero-Ortiz V, Farré-Alegre J, Pérez-Ruixo JJ.
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):693-704. PubMed ID: 23274396
    [Abstract] [Full Text] [Related]

  • 35. The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer.
    Wakelee HA, Takimoto CH, Lopez-Anaya A, Chu Q, Middleton G, Dunlop D, Ramlau R, Leighl N, Rowinsky EK, Hao D, Zatloukal P, Jacobs CD, Rodon J.
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):563-71. PubMed ID: 22057855
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Microalbuminuria during cisplatin therapy: relation with pharmacokinetics and implications for nephroprotection.
    Kern W, Braess J, Kaufmann CC, Wilde S, Schleyer E, Hiddemann W.
    Anticancer Res; 2000 Feb; 20(5C):3679-88. PubMed ID: 11268439
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.